| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Amino-PEG6-alcohol does not have a specific biological target, as it is a chemical linker rather than a pharmacologically active compound. Its function is purely structural, serving as a covalent connector between two or more molecular components. The "targets" of this linker are the specific functional groups on the molecules it is designed to conjugate. The primary amine group is a target for conjugation with molecules that contain carboxylic acids or activated esters (e.g., NHS esters). This reaction forms a stable amide bond. The hydroxyl group can also serve as a target for further functionalization, for instance by converting it to a mesylate or tosylate to make it a better leaving group for subsequent reactions, or by oxidizing it to an aldehyde or carboxylic acid. The PEG6 spacer is not a target but a structural element that interacts with the aqueous environment, enhancing solubility and reducing steric hindrance. Therefore, Amino-PEG6-alcohol acts as a versatile connector, enabling the precise and stable assembly of complex molecular architectures. Its lack of biological activity makes it an inert and biocompatible building block.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system.
As a chemical linker, Amino-PEG6-alcohol does not possess any direct in vitro biological activity, such as enzyme inhibition, receptor binding, or cytotoxicity. Its function is not to interact with biological targets to produce a pharmacological effect, but to serve as a covalent bridge in the synthesis of bioactive conjugates. The in vitro activity of Amino-PEG6-alcohol is therefore assessed indirectly, through the characterization of the conjugates it helps to create. For instance, when used to synthesize an ADC, the activity of the final conjugate is evaluated in cell-based assays for target binding, internalization, and cytotoxicity. The PEG6 linker contributes to the conjugate's overall activity by enhancing its solubility and providing the necessary spacing between the antibody and the drug. In PROTAC synthesis, the linker's role is to connect the target protein ligand and the E3 ligase ligand in the correct orientation and distance. The length and flexibility of the PEG6 spacer are critical for the formation of the ternary complex and the subsequent ubiquitination and degradation of the target protein. Thus, the activity of Amino-PEG6-alcohol is a function of its utility as a synthetic building block. |
| ln Vivo |
As a chemical linker, Amino-PEG6-alcohol does not possess any direct in vivo biological activity. It is not administered as a therapeutic agent and does not exert pharmacological effects in animal models. Its in vivo relevance is strictly as a component of larger, biologically active conjugates. When incorporated into an ADC, the PEG6 linker contributes to the overall in vivo behavior of the conjugate. The hydrophilic PEG spacer is known to improve the pharmacokinetic profile of bioconjugates by increasing their solubility, reducing aggregation, and shielding them from immune recognition, thereby extending their circulation half-life. The specific length of the PEG6 spacer can be optimized to balance these properties. However, the specific in vivo activity—such as tumor regression in a xenograft model—is determined by the conjugate's warhead and targeting ligand, not the linker itself. The linker's role is permissive, ensuring that the active components are stably connected and function optimally in the complex in vivo environment. Therefore, while Amino-PEG6-alcohol is a critical component in the design of effective in vivo therapeutics, its own in vivo activity is negligible.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for Amino-PEG6-alcohol, as it is not a biologically active compound that directly interacts with proteins. The compound is a chemical reagent, and its characterization is performed using analytical chemistry techniques rather than biological assays. The quality and identity of the linker are typically confirmed by methods such as Nuclear Magnetic Resonance (NMR) spectroscopy, High-Performance Liquid Chromatography (HPLC), and Mass Spectrometry (MS) to verify its structure and purity. If an assay were to be conducted to confirm its reactivity, it would be a chemical conjugation reaction rather than a biological binding assay. For example, the amine group's reactivity could be tested by reacting it with an NHS-ester-containing compound and monitoring the formation of the amide bond by HPLC or LC-MS. This is a quality control step to ensure the linker is functional. There are no biological assays for this compound.
|
| Cell Assay |
There are no standard in vitro cell-based assays for Amino-PEG6-alcohol, as it is not a bioactive molecule intended to affect cellular function. Its use in cell biology is indirect, as a reagent for modifying other molecules. For example, it can be used to create ADCs or PROTACs that are then tested in cell-based assays. In such cases, the cell-based assay would involve treating cells with the final conjugated therapeutic and then measuring a biological readout, such as cell viability (for an ADC's cytotoxicity) or target protein levels (for a PROTAC's degradation activity). The performance of the linker would be evaluated by the potency and selectivity of the conjugate, which depend on the linker's ability to connect the components effectively. However, there is no direct assay for the linker itself in cells, as it is not designed to interact with cells in its unconjugated form. The compound's solubility ensures it can be used effectively in these applications without causing cellular artifacts. Any cell-based work involving Amino-PEG6-alcohol is always part of a larger experimental design.
|
| Animal Protocol |
Amino-PEG6-alcohol is not used in in vivo animal experiments as a standalone compound, as it has no direct biological activity. It is a synthetic building block and not a therapeutic agent. Animal studies involving this compound would only be conducted on the final, larger conjugates (such as ADCs or PROTACs) that incorporate it. In such studies, the linker's contribution to the overall pharmacokinetic and pharmacodynamic profile of the conjugate would be assessed. For example, researchers might compare the in vivo efficacy and half-life of an ADC synthesized with Amino-PEG6-alcohol to one synthesized with a different linker (e.g., a shorter or longer PEG linker). The PEG6 spacer is expected to provide good solubility and flexibility, which could translate to a favorable PK profile and efficacy. However, there is no standard animal protocol for Amino-PEG6-alcohol itself. Its use is limited to the research and development phase, where it is employed in the chemical synthesis of test articles. The storage recommendations are for maintaining the chemical integrity of the reagent. In summary, there are no in vivo animal experiments for Amino-PEG6-alcohol as a single agent.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Amino-PEG6-alcohol are not studied as it is not a therapeutic agent. However, its physicochemical properties provide insight into its behavior. It has a molecular weight of 281.35 g/mol and a molecular formula of C12H27NO6, indicating it is a small, highly polar molecule with a logP that is expected to be negative (hydrophilic). This high water solubility is a key feature of the PEG moiety, which is often used to improve the solubility, stability, and circulation time of conjugated therapeutics, reducing immunogenicity and renal clearance. As a small, hydrophilic molecule, it would be expected to have a short half-life if introduced into the bloodstream, likely being rapidly cleared by renal filtration. However, when conjugated to larger molecules like antibodies, the overall PK is dominated by the larger component. The compound is a solid and is soluble in DMSO. For storage, it is recommended to keep it at -20°C. The "PK" properties of this linker are thus not an independent consideration but are integral to the design and performance of the bioconjugates it helps to create.
|
| Toxicity/Toxicokinetics |
Amino-PEG6-alcohol is considered to have low toxicity, consistent with other PEG-based linkers. PEG polymers are widely regarded as biocompatible, non-toxic, and non-immunogenic, which is why they are frequently used in pharmaceuticals and biomedical research. The compound is classified as a research reagent, and standard laboratory safety precautions should be followed when handling it. Its toxicity profile has not been extensively studied, but due to its intended use and chemical class, it is not expected to be acutely toxic. The compound is a non-cleavable linker, meaning it is designed to be stable and not degrade under physiological conditions. This stability is a desirable feature for its intended use, but it also means that if it were to enter the body as part of a conjugate, it would not be readily broken down, which could have long-term implications. However, for its use in vitro and in the synthesis of research compounds, this is not a concern. All handling should be done with appropriate personal protective equipment (PPE) in a well-ventilated area, and the compound should be stored properly to prevent degradation.
|
| References | |
| Additional Infomation |
Amino-PEG6-alcohol is a research-use-only reagent and is not a drug, nor is it approved for any clinical or therapeutic use. It is a highly versatile chemical tool with a key application in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. Its structure, featuring a primary amine and a hydroxyl group separated by a six-unit PEG spacer, makes it a valuable building block for bioconjugation. The amine group allows for stable conjugation to carboxylates or activated esters, while the hydroxyl group can be used for further functionalization or left to enhance solubility. The PEG6 spacer provides a specific length and flexibility that can be optimized for the biological activity of the final conjugate. This specific length offers a balance between hydrophilicity and flexibility, which is important for achieving the desired pharmacokinetic and pharmacodynamic properties of the conjugate. As a non-cleavable linker, it ensures stable attachment of the components, which is suitable for applications where controlled release is not required. It is a standard reagent in medicinal chemistry and chemical biology for creating stable, well-defined conjugates for both in vitro and in vivo research.
|
| Molecular Formula |
C12H27NO6
|
|---|---|
| Molecular Weight |
281.34588
|
| Exact Mass |
281.183
|
| CAS # |
39160-70-8
|
| Related CAS # |
39160-70-8;
|
| PubChem CID |
20554065
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
388.0±37.0 °C at 760 mmHg
|
| Flash Point |
188.5±26.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.463
|
| LogP |
-2.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
19
|
| Complexity |
161
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ICUIZKMGHRMMDZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H27NO6/c13-1-3-15-5-7-17-9-11-19-12-10-18-8-6-16-4-2-14/h14H,1-13H2
|
| Chemical Name |
2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5543 mL | 17.7715 mL | 35.5429 mL | |
| 5 mM | 0.7109 mL | 3.5543 mL | 7.1086 mL | |
| 10 mM | 0.3554 mL | 1.7771 mL | 3.5543 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06124157 | NOT YET RECRUITING | Procedure: Biospecimen Collection Biological: Blinatumomab Procedure: Bone Marrow Biopsy |
B Acute Lymphoblastic Leukemia | National Cancer Institute (NCI) | 2024-07-22 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA